Compare Stocks: ATXI, PHXM, MDCX, and ENSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.57 -5.0%	$0.36	$0.15 ▼ $0.97	$1.88M	-0.18	6,477 shs	14,061 shs
ENSC Ensysce Biosciences	$0.50 +1.7%	$0.36	$0.23 ▼ $2.75	$9.63M	0.97	8.09 million shs	178,316 shs
MDCX Medicus Pharma	$0.15 -5.3%	$0.30	$0.14 ▼ $3.05	$9.79M	0.12	4.11 million shs	3.50 million shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	+10.19%	+132.92%	+87.50%	-26.83%
ENSC Ensysce Biosciences	0.00%	+6.85%	+21.76%	+80.40%	-76.92%
MDCX Medicus Pharma	0.00%	-5.47%	-41.95%	-49.19%	-93.25%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.57 -5.0%	$0.36	$0.15 ▼ $0.97	$1.88M	-0.18	6,477 shs	14,061 shs
ENSC Ensysce Biosciences	$0.50 +1.7%	$0.36	$0.23 ▼ $2.75	$9.63M	0.97	8.09 million shs	178,316 shs
MDCX Medicus Pharma	$0.15 -5.3%	$0.30	$0.14 ▼ $3.05	$9.79M	0.12	4.11 million shs	3.50 million shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	+10.19%	+132.92%	+87.50%	-26.83%
ENSC Ensysce Biosciences	0.00%	+6.85%	+21.76%	+80.40%	-76.92%
MDCX Medicus Pharma	0.00%	-5.47%	-41.95%	-49.19%	-93.25%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
ENSC Ensysce Biosciences	1.00	Sell	N/A	N/A
MDCX Medicus Pharma	2.40	Hold	$9.00	5,744.16% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATXI, PHXM, MDCX, and ENSC Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/17/2026	ENSC Ensysce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
ENSC Ensysce Biosciences	$5.07M	1.90	N/A	N/A	$0.63 per share	0.79
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$0.85	0.03	N/A	N/A	N/A	-471.57%	-296.50%	11/13/2026 (Estimated)
ENSC Ensysce Biosciences	-$10.18M	-$2.76	N/A	N/A	N/A	-280.53%	-2,550.30%	-320.49%	11/13/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
PHXM PHAXIAM Therapeutics	-$240K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ATXI, PHXM, MDCX, and ENSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	ENSC Ensysce Biosciences	-$0.20	-$0.20	N/A	-$0.20	$1.20 million	$1.16 million
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
ENSC Ensysce Biosciences	N/A	0.70	0.70
MDCX Medicus Pharma	N/A	1.57	1.57
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
ENSC Ensysce Biosciences	5.63%
MDCX Medicus Pharma	N/A
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	8.60%
ENSC Ensysce Biosciences	2.80%
MDCX Medicus Pharma	8.10%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.30 million	2.02 million	Not Optionable
ENSC Ensysce Biosciences	10	19.46 million	18.91 million	Not Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

ATXI, PHXM, MDCX, and ENSC Headlines

Recent News About These Companies

PHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJ

July 18, 2025 | wsj.com

Phaxiam Therapeutics SA (PHXM) Stock Forums - Investing.com

June 27, 2025 | investing.com

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 30, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI, PHXM, MDCX, and ENSC Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.57 -0.03 (-5.00%)

As of 10:44 AM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Ensysce Biosciences NASDAQ:ENSC

$0.50 +0.01 (+1.66%)

As of 11:36 AM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Medicus Pharma NASDAQ:MDCX

$0.15 -0.01 (-5.29%)

As of 11:37 AM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 09/11/2026

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXI, PHXM, MDCX, and ENSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXI, PHXM, MDCX, and ENSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXI, PHXM, MDCX, and ENSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI, PHXM, MDCX, and ENSC Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Ensysce Biosciences NASDAQ:ENSC

Medicus Pharma NASDAQ:MDCX

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXI, PHXM, MDCX, and ENSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXI, PHXM, MDCX, and ENSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXI, PHXM, MDCX, and ENSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI, PHXM, MDCX, and ENSC Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Ensysce Biosciences NASDAQ:ENSC

Medicus Pharma NASDAQ:MDCX

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools